ICM
CNMD icon

Invenomic Capital Management’s CONMED CNMD Stock Holding History

Invenomic Capital Management’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.6M Sell
842,162
-92,439
-10% -$3.33M 1.65% 19
2026
Q1 		$33M Buy
934,601
+197,055
+27% +$8.02M 1.52% 21
2025
Q4 		$29.9M Buy
737,546
+317,543
+76% +$13.8M 1.39% 20
2025
Q3 		$19.8M Buy
+420,003
New +$21.8M 0.96% 34

Other funds holding CNMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invenomic Capital Management's CNMD Position: Q2 2026 in Review

Invenomic Capital Management reduced its CONMED (CNMD) stake by 9.9% in Q2 2026, selling an estimated $3.33M and leaving 842,162 shares worth $27.6M. The position accounts for 1.65% of the portfolio, ranked #19.

Invenomic Capital Management first reported a position in CNMD in Q3 2025 and has held it in 4 quarters since. The position peaked at $33M in Q1 2026. 247 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

  • Invenomic Capital Management held 842,162 shares of CONMED worth $27.6M as of Q2 2026.
  • Invenomic Capital Management sold 92,439 CONMED shares in Q2 2026, an estimated $3.33M.
  • CONMED made up 1.65% of Invenomic Capital Management's portfolio in Q2 2026, its #19 holding.
  • Invenomic Capital Management first reported a position in CONMED in Q3 2025 and has held it in 4 quarters since.
  • Invenomic Capital Management's CONMED position peaked at $33M in Q1 2026.
  • 247 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.